Physician profile
Keith Brian Tom
NPI 1609850130
$4,629.40
in general payments reported to CMS, 2019-2025
22 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $880 · 2021: $1,136 · 2022: $792 · 2023: $265 · 2024: $133 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $660.21 | 2021-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $597.74 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $583.09 | 2019-2022 | |
| Amgen INC. | $566.39 | 2019-2024 | Krystexxa |
| Glaxosmithkline, LLC. | $502.65 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $446.35 | 2019-2025 | Wegovy |
| Pfizer INC. | $291.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $269.54 | 2019-2025 | Breztri, Airsupra |
| Medicure Pharma INC. | $123.84 | 2020-2022 | |
| Allergan, INC. | $123.62 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.29 | 2020-2024 | Xifaxan |
| Amarin Pharma, INC. | $69.46 | 2020-2021 | |
| Astellas Pharma US INC | $61.16 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $43.90 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $41.54 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $36.27 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $24.47 | 2019-2022 | |
| Exact Sciences Corporation | $23.45 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $21.78 | 2023 | Xarelto |
| Currax Pharmaceuticals LLC | $14.86 | 2024 | Contrave |
| Biohaven Pharmaceuticals, INC. | $14.35 | 2021 | |
| Mylan Specialty L.P. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Tom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.